{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,5]],"date-time":"2026-05-05T14:15:19Z","timestamp":1777990519817,"version":"3.51.4"},"reference-count":24,"publisher":"MDPI AG","issue":"9","license":[{"start":{"date-parts":[[2026,5,5]],"date-time":"2026-05-05T00:00:00Z","timestamp":1777939200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCM"],"abstract":"<jats:p>Background\/Objectives: Insulin glargine U300 (IGlarU300) is a second-generation, long-acting insulin analog designed to provide a more stable pharmacokinetic profile compared to insulin glargine U100. However, long-term real-world data reflecting its long-term impact on glycemic control and hypoglycemia across diverse populations remain limited. This study evaluated the 24-month clinical outcomes of transitioning to IGlarU300 in a real-world setting. Methods: This retrospective, single-center, observational study enrolled patients with type 1 (T1DM) or type 2 diabetes mellitus (T2DM) who transitioned to IGlarU300 between 2017 and 2021. HbA1c levels, body weight, insulin doses, and hypoglycemia rates were evaluated at baseline and up to 24 months. Results: A total of 242 patients (T1DM: n = 68, T2DM: n = 174) were analyzed. HbA1c levels significantly declined at all follow-up points compared to baseline (mean change at 12 months: \u22120.85% [95% CI: \u22121.24 to \u22120.47%]; p &lt; 0.001]). No significant change in total insulin dose was observed over the one-year follow-up; however, improved glycemic control led to a significant reduction in oral antidiabetic medication use, reflecting successful treatment simplification and a decrease in polypharmacy burden (mean change: -0.50 [95% CI: \u22120.70 to \u22120.30]; p &lt; 0.001). Notably, both severe and mild hypoglycemia episodes showed significant reductions (p = 0.010 and p = 0.019, respectively). Switching to IGlarU300 was associated with sustained improvements in glycemic control and a reduction in hypoglycemia rates. Conclusions: These findings suggest that IGlarU300 may be an effective clinical option for optimizing metabolic outcomes, though further controlled studies are warranted to confirm these observational results.<\/jats:p>","DOI":"10.3390\/jcm15093529","type":"journal-article","created":{"date-parts":[[2026,5,5]],"date-time":"2026-05-05T13:23:37Z","timestamp":1777987417000},"page":"3529","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Clinical Outcomes of Insulin Glargine U300 on Glycemic Control and Hypoglycemia: A Retrospective Observational Study"],"prefix":"10.3390","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8915-9178","authenticated-orcid":false,"given":"G\u00f6k\u00e7en","family":"G\u00fcng\u00f6r Semiz","sequence":"first","affiliation":[{"name":"Division of Endocrinology and Metabolism, Department of Internal Medicine, Faculty of Medicine, Dokuz Eylul University, 35330 \u0130zmir, T\u00fcrkiye"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8000-5220","authenticated-orcid":false,"given":"Mehmet \u00c7a\u011fr\u0131","family":"\u00dcnal","sequence":"additional","affiliation":[{"name":"Division of Endocrinology and Metabolism, Department of Internal Medicine, Faculty of Medicine, Dokuz Eylul University, 35330 \u0130zmir, T\u00fcrkiye"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"\u0130smail","family":"Selimo\u011flu","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Faculty of Medicine, Dokuz Eylul University, 35330 Izmir, T\u00fcrkiye"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S\u0131la","family":"Kalender","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Faculty of Medicine, Dokuz Eylul University, 35330 Izmir, T\u00fcrkiye"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ege","family":"Erbay","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Faculty of Medicine, Dokuz Eylul University, 35330 Izmir, T\u00fcrkiye"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0492-5129","authenticated-orcid":false,"given":"Mehmet Emin","family":"Arayici","sequence":"additional","affiliation":[{"name":"Department of Biostatistics and Medical Informatics Faculty of Medicine, Dokuz Eyl\u00fcl University, 35340 \u0130zmir, T\u00fcrkiye"},{"name":"Department of Public Health, Faculty of Medicine, Dokuz Eyl\u00fcl University, 35330 \u0130zmir, T\u00fcrkiye"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Abdurrahman","family":"\u00c7\u00f6mlek\u00e7i","sequence":"additional","affiliation":[{"name":"Division of Endocrinology and Metabolism, Department of Internal Medicine, Faculty of Medicine, Dokuz Eylul University, 35330 \u0130zmir, T\u00fcrkiye"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Serkan","family":"Yener","sequence":"additional","affiliation":[{"name":"Division of Endocrinology and Metabolism, Department of Internal Medicine, Faculty of Medicine, Dokuz Eylul University, 35330 \u0130zmir, T\u00fcrkiye"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tevfik","family":"Demir","sequence":"additional","affiliation":[{"name":"Division of Endocrinology and Metabolism, Department of Internal Medicine, Faculty of Medicine, Dokuz Eylul University, 35330 \u0130zmir, T\u00fcrkiye"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2026,5,5]]},"reference":[{"key":"ref_1","unstructured":"Magliano, D.J., and Boyko, E.J. (2025). Diabetes Atlas, International Diabetes Federation. [11th ed.]."},{"key":"ref_2","doi-asserted-by":"crossref","unstructured":"Jakubiak, G.K., Pawlas, N., Starzak, M., Blachut, D., Chwalba, A., Wojciechowska, C., and Cie\u015blar, G. (2026). Analysis of the Relationship Between Glycated Hemoglobin and Echocardiographic Parameters in Patients Without Diabetes: A Retrospective Study. J. Clin. Med., 15.","DOI":"10.3390\/jcm15010033"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"2084","DOI":"10.2337\/dc13-2908","article-title":"Comparison of Insulin Degludec\/Insulin Aspart and Biphasic Insulin Aspart 30 in Uncontrolled, Insulin-Treated Type 2 Diabetes: A Phase 3a, Randomized, Treat-to-Target Trial","volume":"37","author":"Fulcher","year":"2014","journal-title":"Diabetes Care"},{"key":"ref_4","doi-asserted-by":"crossref","unstructured":"American Diabetes Association (2019). 9. Pharmacologic Approaches to Glycemic Treatment: Standards of Medical Care in Diabetes\u20142019. Diabetes Care, 42, S90\u2013S102.","DOI":"10.2337\/dc19-S009"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1499","DOI":"10.2337\/dc13-2743","article-title":"Insulin Therapy in People with Type 2 Diabetes: Opportunities and Challenges?","volume":"37","author":"Home","year":"2014","journal-title":"Diabetes Care"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"3411","DOI":"10.2337\/dc13-0331","article-title":"Clinical inertia in people with type 2 diabetes: A retrospective cohort study of more than 80,000 people","volume":"36","author":"Khunti","year":"2013","journal-title":"Diabetes Care"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"450","DOI":"10.2337\/dc09-2132","article-title":"Barriers to Achieving Glycemic Targets: Who Omits Insulin and Why?","volume":"33","author":"Weinger","year":"2010","journal-title":"Diabetes Care"},{"key":"ref_8","first-page":"155","article-title":"Avoiding hypoglycemia: A key to success for glucose-lowering therapy in type 2 diabetes","volume":"2013","year":"2013","journal-title":"Vasc. Health Risk Manag."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1056\/NEJMra040832","article-title":"Insulin Analogues","volume":"352","author":"Hirsch","year":"2005","journal-title":"New Engl. J. Med."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.pec.2007.05.003","article-title":"A critical review of the literature on fear of hypoglycemia in diabetes: Implications for weight gain and glycemic control","volume":"68","author":"Wild","year":"2007","journal-title":"Patient Educ. Couns."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1111\/jdi.12894","article-title":"Comparison of insulin glargine 300 U\/mL and insulin degludec using flash glucose monitoring: A randomized cross-over study","volume":"10","author":"Yamabe","year":"2019","journal-title":"J. Diabetes Investig."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"e14377","DOI":"10.1111\/ijcp.14377","article-title":"Clinical research of insulin glargine U300 basal-bolus therapy and insulin degludec\/aspart co-formulation in type 2 diabetes mellitus: A real world experience","volume":"75","author":"Kisioglu","year":"2021","journal-title":"Int. J. Clin. Pract."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"637","DOI":"10.2337\/dc14-0006","article-title":"New Insulin Glargine 300 Units\u00b7mL\u22121 Provides a More Even Activity Profile and Prolonged Glycemic Control at Steady State Compared with Insulin Glargine 100 Units\u00b7mL\u22121","volume":"38","author":"Becker","year":"2015","journal-title":"Diabetes Care"},{"key":"ref_14","doi-asserted-by":"crossref","unstructured":"American Diabetes Association Professional Practice Committee (2022). 2. Classification and Diagnosis of Diabetes: Standards of Medical Care in Diabetes\u20142022. Diabetes Care, 45, S17\u2013S38.","DOI":"10.2337\/dc22-S002"},{"key":"ref_15","unstructured":"Turkish Society of Endocrinology and Metabolism (2022). Diabetes Mellitus ve Komplikasyonlar\u0131n\u0131n Tan\u0131, Tedavi ve \u0130zlem K\u0131lavuzu [Guidelines for the Diagnosis, Treatment, and Follow-up of Diabetes Mellitus and its Complications], Turkish Society of Endocrinology and Metabolism. [15th ed.]. Available online: http:\/\/www.temd.org.tr."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"52","DOI":"10.5005\/jp-journals-10070-7031","article-title":"Early initiation of insulin therapy in newly diagnosed patients with type 2 diabetes and exploring the legacy effect\u2014A single-arm prospective observational study","volume":"7","author":"Samajdar","year":"2020","journal-title":"Bengal Physician J."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/S0140-6736(24)00537-3","article-title":"Post-trial monitoring of a randomised controlled trial of intensive glycaemic control in type 2 diabetes: 44-year follow-up of UKPDS 91","volume":"404","author":"Adler","year":"2024","journal-title":"Lancet"},{"key":"ref_18","unstructured":"American Diabetes Association Professional Practice Committee (2026). Standards of Care in Diabetes\u20142026. Diabetes Care, 49, S1\u2013S324."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1821","DOI":"10.1080\/03007995.2017.1335192","article-title":"Understanding how pharmacokinetic and pharmacodynamic differences of basal analog insulins influence clinical practice","volume":"33","author":"Goldman","year":"2017","journal-title":"Curr. Med. Res. Opin."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"2869","DOI":"10.1111\/dom.15178","article-title":"Evaluating the clinical effectiveness and safety of insulin glargine 300 U\/mL in individuals with type 2 diabetes uncontrolled on basal insulin: A real-world evidence study from Saudi Arabia (EVOLUTION)","volume":"25","author":"Othman","year":"2023","journal-title":"Diabetes Obes. Metab."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"4","DOI":"10.5152\/erp.2024.23311","article-title":"Effectiveness and safety of \u0131nitiation and titration of \u0131nsulin glargine 300 U\/mL in \u0131nsulin-naive patients with type 2 diabetes mellitus uncontrolled on oral antidiabetic drug treatment in Turkey: The EASE study","volume":"28","author":"Kaya","year":"2024","journal-title":"Endocrinol. Res. Pract."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"1589","DOI":"10.1111\/dom.15007","article-title":"Comparative clinical efficacy and safety of insulin glargine 300\u2009U\/ml (Toujeo) versus insulin glargine 100\u2009U\/ml in type 2 diabetes and type 1 diabetes: A systematic literature review and meta-analysis","volume":"25","author":"Joshi","year":"2023","journal-title":"Diabetes Obes. Metab."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1007\/s13300-024-01537-2","article-title":"Real-World Study on Effectiveness of Insulin Glargine U300 After Oral Antidiabetic Drug Failure in Patients with Type 2 Diabetes in the Gulf Region","volume":"15","author":"Khan","year":"2024","journal-title":"Diabetes Ther."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"426","DOI":"10.4103\/ijem.ijem_57_23","article-title":"Real-world Clinical Effectiveness on Glycaemic Parameters, Safety and Additional Benefits of Glargine U300 (Toujeo\u00ae) Initiation after Oral Antidiabetic Drug Failure in Insulin-na\u00efve Patients with type 2 Diabetes Mellitus","volume":"27","author":"Shah","year":"2023","journal-title":"Indian J. Endocrinol. Metab."}],"container-title":["Journal of Clinical Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2077-0383\/15\/9\/3529\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,5]],"date-time":"2026-05-05T13:46:45Z","timestamp":1777988805000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2077-0383\/15\/9\/3529"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,5]]},"references-count":24,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2026,5]]}},"alternative-id":["jcm15093529"],"URL":"https:\/\/doi.org\/10.3390\/jcm15093529","relation":{},"ISSN":["2077-0383"],"issn-type":[{"value":"2077-0383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,5]]}}}